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Abstract
Molecular tests may enable early adjustment of antimicrobial therapy and be complementary to blood culture (BC) which has
imperfect sensitivity in critically ill patients. We evaluated a novel multiplex real-time PCR assay to diagnose bloodstream
pathogens directly in whole blood samples (BSI-PCR). BSI-PCR included 11 species- and four genus-specific PCRs, a molecular
Gram-stain PCR, and two antibiotic resistance markers. We collected 5 mL blood from critically ill patients simultaneously with
clinically indicated BC. Microbial DNA was isolated using the Polaris method followed by automated DNA extraction.
Sensitivity and specificity were calculated using BC as reference. BSI-PCR was evaluated in 347 BC-positive samples
(representing up to 50 instances of each pathogen covered by the test) and 200 BC-negative samples. Bacterial species-
specific PCR sensitivities ranged from 65 to 100%. Sensitivity was 26% for the Gram-positive PCR, 32% for the Gram-
negative PCR, and ranged 0 to 7% for yeast PCRs. Yeast detection was improved to 40% in a smaller set-up. There was no
overall association between BSI-PCR sensitivity and time-to-positivity of BC (which was highly variable), yet Ct-values were
lower for true-positive versus false-positive PCR results. False-positive results were observed in 84 (4%) of the 2200 species-
specific PCRs in 200 culture-negative samples, and ranged from 0 to 6% for generic PCRs. Sensitivity of BSI-PCR was
promising for individual bacterial pathogens, but still insufficient for yeasts and generic PCRs. Further development of BSI-
PCR will focus on improving sensitivity by increasing input volumes and on subsequent implementation as a bedside test.
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Introduction
Rapid detection and identification of a causative pathogen is
essential in the treatment of critically ill patients with blood
stream infection (BSI), since timely initiation of adequate an-
tibiotic treatment is associated with decreased morbidity, mor-
tality, and possibly reduced healthcare costs [1–5].
Furthermore, faster pathogen identification may limit the in-
appropriate use of antimicrobial drugs and consequently may
reduce development of antibiotic resistance [1]. Conventional
culture of inoculated blood samples, termed blood culture
(BC), is currently considered the Bgold standard^ for diagnos-
ing BSI. However, its diagnostic accuracy may be hampered
by concomitant antibiotic treatment, low levels of circulating
bacteria, and poor sensitivity for slow growing, intracellular,
and fastidious microorganisms [2, 6, 7]. In addition, BC re-
quires between 24 and 72 h to yield final results [7].
Polymerase chain reaction (PCR)-based assays performed
directly on whole blood may complement BC, by yielding
faster results and improving pathogen detection [7]. In contrast
to molecular tests performed on bacterial isolates, these assays
are independent of time-consuming culture methods. However,
highly variable diagnostic performance has been reported, both
for the most widely studied LightCycler SeptiFast (LSF) test
(Roche Diagnostics GmbH, Mannheim, Germany) [8, 9], as
well as for various other PCR-based detection technologies
[10–12]. In an open-label, cluster-randomized, interventional
crossover trial, the use of LSF test in septic patients increased
the proportion of patients with a microbiological diagnosis, but
failed to reduce 7-day mortality [13]. Consequently, the utility
of these tests during routine clinical practice remains unclear as
molecular techniques continue to be refined [2, 14]. For exam-
ple, the efficacy of the LSF test may be impeded by lengthy
hands-on time (ranging 5–7 h) and its sensitivity may be com-
promised by the use of relatively low blood volumes for anal-
ysis (i.e., an equivalent of 0.17 mL of blood per PCR tested).
We developed a novel multiplex real-time PCR assay
(which will further be referred to as BSI-PCR) for detecting
microbial DNA directly in relatively large-volume whole
blood samples (5 mL) of patients with presumed infection,
targeting the bacteria, fungi, and resistance markers consid-
ered most relevant for intensive care unit (ICU) populations
[15, 16]. In the near future, this assay will be implemented in a
point-of-care platform requiring only very little hands-on time
and yielding results within 3 h. This will enable physicians to
confirm the presence of infection and adjust the empirical
antimicrobial regimen early, while BCs are still being proc-
essed. In this manuscript, we describe essential steps taken
during BSI-PCR development so far, and report a first system-
atic evaluation of test characteristics in a large selection of
clinical blood samples obtained from ICU patients with
suspected infection. Of note, this study did not (yet) aim to
evaluate the clinical impact of the new multiplex PCR on
diagnostic reasoning and merely focuses on sensitivity of in-
dividual PCRs rather than predictive values or specificity of
BSI-PCR as a whole.
Materials and methods
BSI-PCR assay design
For detection of pathogens at species level, we designed
novel PCRs for Escherichia (E.) coli, Enterococcus (E.)
faecium, E. faecalis, Acinetobacter (A.) baumannii, and
Staphylococcus (S.) aureus, because previously reported
assays were not sufficiently specific or inclusive in silico
analyses (Table 1). We aimed to find multi-copy targets on
the genome to increase sensitivity by using the PCR
MultiMPrimer3 tool [25]. This resulted in 2-copy targets
for both E. coli and S. aureus. For E. faecalis a 3–4 copy
target was found in the sequence encoding RNA previous-
ly designated as non-coding [26]. For A. baumannii, a 6-
copy target was identified in the 23S rRNA gene. The
Insignia tool [27] provided a single copy species-specific
sequence for E. faecalis. We also included a broad PCR
that detects less prevalent pathogens; this PCR which we
refer to as molecular Gram stain, discriminates clinically
relevant Gram-negatives from Gram-positives [19].
Furthermore, detection of Candida species, Aspergillus
and the resistance markers mecA and CTX-M1,9 were
added to the test. Presence of CNS was inferred from pos-
itivity in the mecA and/or Staphylococcus genus PCR and
negativity in the S. aureus PCR.
Primers and probes were designed by MultiMPrimer3
or PrimerExpress (ABI) and their genomic targets are pro-
vided in Table 1. PCR amplicons were regularly tested for
specificity and coverage in silico, as during the course of
this study continuously new genome sequences became
available. An internal control PCR was developed for
each multiplex reaction by constructing a plasmid con-
taining two primer sequences of the multiplex with an
artificial probe sequence in between. Primers comprised
of BSI-PCR target sequences and sequences complemen-
tary to pICwhi2 were used to generate an amplicon using
pICwhi2 as template [24]. The amplicon was cloned into
pGEM-T-easy, transformed into E. coli DH5a and then
sequenced. Purified plasmid was added to each multiplex
PCR mix in a concentration of approximately 150 plasmid
copies per PCR reaction. The complete lay-out of the
BSI-PCR assay is shown in Table 2.
PCR reactions were performed on a LightCycler 480
II (Roche Diagnostics). Reaction mixtures contained
12.5 μL SensiMix II (Bioline) plus 2.5 μL primers and
probes (Biolegio and Biosearch). For each sample, 10 μL
DNA, representing 0.71 mL of blood, was added per
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PCR reaction. Used cycling conditions were 10 min of
95 °C followed by 45 cycles of 95 °C for 15 s and 60 °C
for 1 min. Results were analyzed with the LightCycler
software version 1.5.0 using Color Compensation to cor-
rect for fluorescence bleed-through. Primer and probes
mixes were prepared in bulk and tested with positive
and negative controls in a separate experiment before
running the samples.
DNA extraction and isolation
DNA isolation from pure cultures was done as previously
described [20]. For pathogen DNA isolation from blood,
blood samples were processed following the 5 mL manual
Polaris protocol [28]. This method ensures chemical lysis of
human cells and degradation of free DNA before isolation and
chemical lysis of pathogens. The resulting pathogen lysates of
Table 1 PCR targets used in the
BSI-PCR assay Pathogen/resistance marker Target Target copy number per cell Reference
A. baumannii 23S rDNA 6 This study
3Candida a, b ITS2 Variable This study, [17]
C. albicans
C. glabrata
C. krusei
CTX-M1,9 blaCTX-M1,9 Variable [18]
E. coli gadA gadB 2 This study
E. faecalis ncRNA Ref12A 3–4 This study
E. faecium Hypothetical ORF 1 This study
Enterococcus genus 23S rDNA 4–6 This study
Gram-neg/pos c 16S rDNA 1–8 Adapted from [19]
Klebsiella species rhaA-rhaD
intergenic region
1 [20]
mecA mecA 1 [21]
Pan-Aspergillus ITS2 Variable [20, 22]
P. aeruginosa phzE 2 [20]
S. aureus hsdM 2 This study
S. pneumoniae comX 2 [23]
Staphylococcus genus tuf 1 Adapted from [20]
IAC Artificial Not applicable [24]
IAC internal amplification control
a 3Candida PCR detects C. albicans, C. tropicalis, and C. parapsilosis
b All Candida species are detected with the same primer set combined with species-specific probes
c Gram-positive/Gram-negative detection is based on one primer pair with two different probes
Table 2 Composition and LightCycler settings of the BSI-PCR assay
Channel settings (Ex-Em) Probe label Multiplex 1 Multiplex 2 Multiplex 3 Multiplex 4
440–488 nm Atto425 Pan-Aspergillus E. coli S. aureus Staphylococcus genus
465–510 nm FAM Gram-positive E. faecium E. faecalis Enterococcus genus
498–580 nm HEX/Yakima Yellow Gram-negative A. baumannii P. aeruginosa Klebsiella species
533–610 nm CalFluor610 3Candida a – C. krusei C. albicans
533–640 nm CalFluor635 C. glabrata mecA S. pneumoniae CTX-M1,9
618–660 nm Atto647N IAC IAC IAC IAC
All PCR reactions were performed on a LightCycler 480 II (Roche Diagnostics).
IAC internal amplification control, Ex excitation wavelength setting, Em emission wavelength setting
a 3Candida PCR detects C. albicans, C. tropicalis C. parapsilosis
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0.22 mL were supplemented with 1 mL of EasyMag lysis
buffer (Biomerieux) to preserve DNA, and stored at − 80 °C
till final analysis. After thawing, the samples were added to
EasyMag containers holding 1 mL of AL buffer (Qiagen),
where after DNA was isolated using the specific A protocol
in an elution volume of 70 μL on an automated EasyMag
device. For each run of 23 samples an isolation control, con-
taining only EasyMag reagents, was taken along. Resulting
DNAwas stored at − 80 °C.
Spiking experiments
Microorganisms were grown to exponential phase in Luria
Broth, diluted in Luria Broth based on optical density mea-
surements, and spiked in 5 mL of blood from healthy volun-
teers to yield loads ranging from 1500 to 1.5 organisms per
milliliter of blood. Suspensions were plated to verify the load-
ings. Spiked blood was processed as described above, except
for the − 80 °C freezing step.
Collection of clinical blood specimens for PCR testing
Clinical blood samples were prospectively collected as part of
the Molecular Diagnosis and Risk Stratification of Sepsis
(MARS) initiative, a prospective cohort study in two tertiary
mixed medical-surgical ICUs in the Netherlands [29]. Ethical
approval for the study was provided by the Medical Ethics
Committee of the University Medical Center Utrecht
(UMCU), including an opt-out consent method (IRB No.
10-056C). From January 2012 till June 2014 blood specimens
(5 mL) for BSI-PCR evaluation were drawn simultaneously
whenever blood cultures were taken on clinical indications
(i.e., at the discretion of the attending physician) by using
the same catheter hub or venipuncture site for collecting an
EDTA blood tube. Samples were anonymized for both patient
characteristics and corresponding culture results by using cod-
ed identifiers. Subsequently, blood samples were stored at
4 °C for a maximum of 3 days before further processing fol-
lowing the protocol described above. All BCs were processed
according to routine clinical protocols in the microbiology
laboratories of both hospitals.
Clinical sample selection
To study both PCR-specific and the overall BSI-PCR perfor-
mance across a wide spectrum of relevant pathogens, we se-
lected blood samples based on the results of the pairwise col-
lected BC. To exclude potentially contaminated BCs, some
predefined criteria were applied for Enterococci and CNS
[30]. For these species, we excluded all samples yielding
polymicrobial growth as well as samples associated with an-
other BC taken on the same day that remained either negative
or yielded any other pathogen. Similarly, we took measures to
reduce the risk that the 200 negative control samples were in
fact resulting from a false negative BC. To this end, we select-
ed only specimens of patients with no positive BC on the same
day, and excluded specimens collected on the first day of post-
surgical ICU-admissions. Among these, 50% of the negative
samples were derived from patients receiving no systemic
antibiotic or antifungal therapy on the day of sampling or
during the 2 days prior to that. For each PCR-target, a maxi-
mum of 50 samples containing at least 4.5 mL of blood were
selected, preferably from different patients. In case of a poly-
microbial BC result, each isolate was assessed separately for
eligibility. PCRs for antibiotic resistance markers were not
evaluated in the clinical samples, because of a low prevalence
of MRSA and ESBL-positive bacteremia in the Netherlands
[31, 32].
Diagnostic evaluation of BSI-PCR
Technicians, who performed all BSI-PCR assays and reported
the results, were blinded for corresponding culture results and
clinical information. Sensitivity and specificity with exact
confidence intervals were calculated for each PCR separately
by using BC as the reference test. For determining specificity,
each individual PCR was evaluated against the same set of
200 negative BC. In contrast, overall sensitivity and specific-
ity of specific pathogen detection by BSI-PCR were evaluated
by combining the results of all 11 species-specific PCRs
contained in the multiplex set-up. Thus, each single blood
sample contributed 11 separate results to this analysis. To
assess whether BSI-PCR detection of pathogens was depen-
dent on pathogen blood load, we performed multiple compar-
isons between samples yielding true positive versus false neg-
ative results. All comparisons between groups were made
using Mann-Whitney U tests or Pearson’s chi-squared test,
as appropriate. All analyses were performed using SAS
Enterprise Guide 7.1 (SAS Institute, Cary, NC) and figures
were made using GraphPad Prism version 7.02 (GraphPad
Software, La Jolla California).
Results
BSI-PCR development
In order to obtain broad coverage of relevant pathogens, we
designed the BSI-PCR assay to include both species- and
genus-specific PCRs, as well as generic PCRs discriminating
a broad panel of Gram-negatives versus Gram-positives (fur-
ther referred to as the molecular Gram stain; Table 2). The
latter PCRs were added in order to cover rare pathogens not
included in specific PCRs. Furthermore, we included PCRs
targeting the resistance markers mecA (present in methicillin-
resistant Staphylococci) and CTX-M1,9 (present in extended
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spectrum β-lactamase producers). All PCRs were first tested
in a monoplex setting and found to be highly specific across a
broad panel of clinically relevant microorganisms (listed in
Table S1). Nineteen monoplex assays were then combined
into 4 multiplex PCRs, each containing a tailored internal
amplification control (Table 2). The analytical sensitivities of
the mono- versus multiplex PCRs were highly comparable
when using DNA derived from spiked blood samples
(Table 3). Furthermore, most PCRs did not generate false-
positive signals in over 100 isolation controls and negative
control blood samples analyzed during test development, ex-
cept for the molecular Gram stain and, occasionally, the
A. baumannii PCR. These false-positive signals probably
originated from chemicals and consumables used during these
tests, which are known to be frequently contaminated with
environmental bacterial DNA [33]. Based on these first obser-
vations, negative cut-off Ct-values were set at 35 cycles for the
A. baumannii and the Gram-positive PCR, and at 33 cycles for
the Gram-negative PCR.
Clinical sample selection
For BSI-PCR validation, a total of 5570 blood cultures
were obtained from 1679 ICU patients, including 732
(13%) specimens yielding growth of one or more micro-
organisms. Following eligibility criteria outlined above,
we first selected samples paired with a BC being positive
for any of the targets included in the BSI-PCR. Overall,
this resulted in 347 samples (yielding 356 isolates) for
validation (Table 4). Similarly, among the available 4838
culture-negative blood specimens, a selection of 200 sam-
ples was made. There were no BCs yielding growth of
A. baumannii, Candida (C.) krusei, C. tropicalis or
Aspergillus species. Therefore, specific PCRs addressing
these targets were assessed analytically during BSI-PCR
development, but could not be further validated. None of
the clinical samples had to be excluded from analysis due
to PCR inhibition (as indicated by the performance of the
internal amplification control PCR).
Sensitivity of BSI-PCR
The sensitivity of individual PCRs within the multiplex
setting was highly variable (Table 4). For bacterial patho-
gens, the observed detection rates ranged from 65 to 100%
for PCRs targeting bacteria at the species level, and from
26 to 57% for PCRs targeting bacteria at their genus or
Gram stain level. Sensitivity was 0 to 7% for PCRs
targeting individual yeasts, and 23% for the 3Candida
PCR targeting three species combined. Overall, BSI-PCR
identified 138 (77%) of the 179 bacterial isolates that the-
oretically should be detected on species level, yet only 1 of
the 41 fungal species. Of the residual 217 undetected
isolates, 136 negative results were explained by the
targeted pathogens not being intrinsically detectable by
species-specific PCRs and 81 undetected pathogens were
due to failure of PCRs. However, 54 (25%) of these iso-
lates were correctly identified on genus level and/or mo-
lecular Gram stain. Sensitivity of BSI-PCR was similar for
the 39 isolates cultured from 30 blood samples yielding a
polymicrobial result, compared to the 317 isolates cultured
from samples yielding only a single microorganism (41
versus 52%, p = 0.21).
Specificity of BSI-PCR
Specificity of individual PCRs ranged from 89 to 100% in
BC-negative samples (Table 4). However, given the multi-
plex setting combining 18 distinct tests, BSI-PCR was con-
sidered (completely) true negative in only 121 (60%) of
200 BC-negative samples. Thus, discordant positive PCR
results were found among 79 culture-negative samples,
yielding a total of 84 species-specific and 26 generic
PCR results. Furthermore, BSI-PCR identified 90 patho-
gens that were non-congruent with BC growth in the 218
culture-positive samples selected for evaluation of species-
specific PCRs. All together there were thus 174 discordant
positive species-specific PCR results occurring among
4598 individual PCRs performed, yielding an overall spec-
ificity of 96%. These detections mainly concerned
S. aureus (n = 43), E. coli (n = 38), and P. aeruginosa
(n = 34; Table 5).
Impact of bacterial load on PCR performance
To assess whether BSI-PCR sensitivity was related to pathogen
load, we correlated time-to-positivity (TTP, a proxy of viable
pathogen load in blood) for a subset of 197 BC-positive sam-
ples to the corresponding PCR results. The median TTP was
19.6 h (interquartile range (IQR) 11.2–32.3) for samples yield-
ing a true positive PCR result and 35.2 h (IQR 16.3–54.1) for
samples yielding a false negative result (Fig. 1). However, this
difference may be partly explained by an overall reduced sen-
sitivity of BSI-PCR for the detection of CNS and Candida
species, the latter being known to be slow growers in conven-
tional BC [34]. Ct-values of species-specific PCRs were sig-
nificantly lower (indicating larger amounts of microbial DNA)
in true positive compared to discordant positive test results
(median Ct 34.4 (IQR 31.5–36.7) versus 38.6 (IQR 36.3–
40.0), p < 0.001; Table 5). However, there was no overall cor-
relation between Ct-value and TTP in a subset of 106 true
positive results (Spearman correlation coefficient 0.15, p =
0.12), although for individual species Ct-values seemed to be
higher at longer TTP except for Staphylococci (Fig. S1).
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Post hoc analyses of discrepant samples
Detection of Candida species in the clinical samples appeared
especially poor. To exclude that underperformance of Candida
PCRs in clinical samples was related to the multiplex set-up of
BSI-PCR, we re-tested isolated DNA of 37 samples of the 45
Candida-positive BC in a simpler format (including only primers
and probes forAspergillus andCandida species). This resulted in
an improved sensitivity for allCandida PCRs, yielding detection
rates for C. albicans and C. glabrata of 41 and 45% at their
species level, respectively. Additionally, all four samples with
C. parapsilosis were now positive in the 3Candida PCR.
Table 3 Analytical sensitivities of monoplex and multiplex PCR for detection of pathogens isolated from spiked blood samples
PCR Detection format Number of genomes per PCR a
1000 100 50 10 1 0
Gram-positive Monoplex 23.5 27 28.1 30.6 33.2 36.6
Multiplex 1 25.5 28.6 29.8 31.2 32.9 33.2
Gram-negative Monoplex 24.0 27.5 28.6 30.9 33.5 33.7
Multiplex 1 26 29.1 30.5 31.9 33 36.9
3Candida Monoplex 27.7 30.8 32.2 34.1 Neg Neg
Multiplex 1 26.6 29.6 31.1 33.0 Neg Neg
C. glabrata Monoplex 28.2 31.6 33.5 34.5 37.8 Neg
Multiplex 1 26.8 30.3 31.3 32.9 Neg Neg
E. coli Monoplex 27.8 31.0 32.1 34.2 38.8 Neg
Multiplex 2 27.5 30.8 31.8 34.1 36.4 Neg
E. faecium Monoplex 30.9 33.8 35.0 37.2 40.0 Neg
Multiplex 2 29.9 32.9 34.3 36.2 39.6 Neg
A. baumannii Monoplex 26.7 29.5 31.1 32.7 37.0 Neg
Multiplex 2 26.5 29.5 30.8 32.7 36.5 Neg
mecA Monoplex 27.0 31.0 34.5 32.5 37.6 Neg
Multiplex 2 27.2 31.2 33.9 32.5 35.9 Neg
S. aureus Monoplex 27.0 30.5 31.8 34.0 38.7 Neg
Multiplex 3 26.5 30.0 31.2 33.8 36.8 Neg
E. faecalis Monoplex 29.6 33.0 34.1 36.3 37.4 Neg
Multiplex 3 28.7 32.0 33.1 35.6 37.0 Neg
P. aeruginosa Monoplex 27.9 30.8 30.9 35.3 38.1 Neg
Multiplex 3 26.9 29.7 30.1 33.8 36.2 Neg
C. krusei Monoplex 29.5 33.6 33.0 Neg Neg Neg
Multiplex 3 26.8 30.2 31.7 32.2 Neg Neg
S. pneumoniae Monoplex 29.0 33.0 33.5 35.9 40 Neg
Multiplex 3 28.7 32.5 33.0 34.6 37.2 Neg
Staphylococcus genus Monoplex 29.3 33.4 33.9 36.4 40 Neg
Multiplex 4 28.7 32.2 33.1 34.0 Neg Neg
Enterococcus genus Monoplex 29.8 33.1 34.1 35.6 36.2 Neg
Multiplex 4 28.9 32.5 33.5 34.8 35.9 Neg
Klebsiella species Monoplex 28.0 31.4 32.3 34.8 40 Neg
Multiplex 4 27.5 30.7 31.7 33.9 36.8 Neg
C. albicans Monoplex 28.6 31.6 33.1 34.8 Neg Neg
Multiplex 4 27.5 30.6 31.8 33.5 Neg Neg
Results are presented as Ct-values obtained in one representative experiment. For each PCR, at least 2 independent spiking experiments were performed. The
Aspergillus and CTX-M-1,9 PCRwere not evaluated in this format as Aspergillus cultures could not reliably be quantified and the CTX-M-1,9 PCRwas not
evaluated in the clinical samples. The sensitivities of these PCRs were evaluated using DNA from pure cultures.
Neg no amplification detected
a Healthy human donor blood was spiked with different concentrations of live pathogens and processed by the Polaris method to yield the indicated
amount of DNA (calculated as number of genomes) per PCR
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Among all pathogens evaluated, 82 bacterial isolates were
not covered by any of the species- or genus-specific PCRs
included in the test. However, 56 of these could potentially
have been detected by the generic Gram stain PCR. Indeed,
this was the case for 3 (12%) out of 26 Gram-positive and 12
(40%) out of 30 Gram-negative pathogens. All remaining 26
non-detected isolates (including Bacteroides, Proteus,
Micrococcus, Eggerthella, and Propionibacterium species)
contain mismatches in primer/probe regions of the 16S
rDNA region targeted by the Gram stain PCRs, which
prevented amplification.
Another portion of failed PCR detection could be due to
unknown variations in the DNA sequence of individual path-
ogen strains, which may cause mismatch of primers and
probes. In our study, this could have been the case for 13
samples containing pathogens that were detected by a generic
PCR, but not by their corresponding species-specific PCR.
Eight of these BC isolates were retrieved from the microbiol-
ogy lab, DNA was extracted from pure culture, and the
samples were then re-tested in a monoplex species-specific
PCR. This resulted in correct pathogen identification in six
(75%) of these samples, excluding DNA sequence variation
as a cause of these detection failures.
Limitations of the reference test
We performed three additional analyses to test the robustness
of our estimations of BSI-PCR sensitivity. First, we assessed
contamination of BC during blood sampling as a possible
cause of false negative PCR results. For this purpose, we ap-
plied extra criteria for the selection of samples used to deter-
mine the sensitivity of the PCRs for Gram-positive bacteria
(which are known to be frequent contaminants of BC). This
resulted in the exclusion of 70 samples from our primary anal-
ysis. As a consequence, detection rates for E. faecalis (79%)
and CNS (52%) improved, but not for other pathogens
(Table S2). Second, we assessed the potential impact of con-
comitant antimicrobial drug use on the observed specificity of
Table 4 Sensitivity and Specificity of BSI-PCR per pathogen or target in clinical samples
Pathogen or target Sensitivity Specificity
BSI-PCR positive /
BC positive
% (95%-CI) BSI-PCR positive in 200
negative BC a
% (95%-CI)
A. Species-specific PCRs
E. faecalis b 20/27 74% (54–89) 5 98% (95–100)
E. faecium b 33/50 66% (51–79) 10 95% (91–98)
S. aureus 28/35 80% (63–92) 22 89% (84–93)
S. pneumoniae 2/2 100% (16–100) 5 98% (94–99)
A. baumannii 0/0 NA 3 99% (97–100)
E. coli 17/19 89% (67–99) 15 93% (88–96)
Klebsiella species 11/17 65% (38–86) 1 100% (97–100)
P. aeruginosa 27/29 93% (77–99) 22 89% (84–93)
C. albicans 0/27 0% (0–13) 0 100% (98–100)
C. glabrata 1/14 7% (0–34) 0 100% (98–100)
C. krusei 0/0 NA 1 100% (97–100)
B. Generic PCRs
Enterococcus genus b 44/77 57% (45–68) 4 98% (95–99)
Staphylococcus genus b 41/85 48% (37–59) 12 94% (90–97)
Coagulase negative Staphylococi b, c 22/50 44% (30–59) 12 94% (90–97)
Gram-positive bacteria d 51/196 26% (20–33) 3 99% (96–100)
Gram-negative bacteria d 37/115 32% (24–42) 5 98% (94–100)
3Candida 7/31 23% (10–41) 0 100% (98–100)
Pan-Aspergillus 0/0 NA 2 99% (96–100)
BC blood culture, CI confidence interval, NA no blood culture isolates available for evaluation
a Each PCR was evaluated in the same set of 200 culture-negative samples
b Selection criteria were applied to reduce the chance of blood culture being discordant positive by contamination
c Inferred from positivity in the mecA and/or Staphylococcus genus PCR and negativity in the S. aureus PCR
d For Gram-positive 8 pathogens were intrinsically not detectable by chosen primers and probes, excluding these resulted into a sensitivity of 27%. For
Gram-negative 19 Bacteroides species were intrinsically not detectable, excluding these resulted into a sensitivity of 38%.
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BSI-PCR. These drugs inhibit growth of viable pathogens
present in BC and may thus be at the cause of an apparently
discrepant PCR result. However, observed discordant positive
rates were 42% for samples collected during antibacterial or
antifungal treatment versus 38% for remaining samples (p =
0.51), making such effect unlikely. Finally, we assessed
whether discrepant positive results of BSI-PCR related to oth-
er culture results observed within 72 h of the index BC sample
(for cultures obtained in the ICU and patients treated in one of
the study centers only). Overall, 23 (13%) of the 181 false-
positive PCR-results in the 130 blood samples included in this
analysis were in concordance to BC findings at a different
time-point, and 66 (36%) results concurred with at least one
culture obtained in the ICU from various other body sites or
specimens (Table S3).
Discussion
We designed a novel multiplex PCR assay for rapid pathogen
identification directly in blood and assessed its diagnostic per-
formance by comparing to BC results obtained from critically
ill patients suspected of infection. Observed sensitivity of BSI-
PCR was relatively high for the majority of individual bacte-
rial pathogens, yet insufficient for yeasts and bacteria groups.
However,Candida detection rates improved when PCRs were
performed using a simplified set-up. Specificity was accept-
able (i.e., > 89%) when PCRs were analyzed individually, but
for the multiplex BSI-PCR taken as whole, discordant positive
results were frequently observed due to the large number in-
dividual tests performed on each sample. Of note, all microbes
that were additionally identified by BSI-PCR in our study
were regarded as spurious (i.e., false positive) findings, yet
in fact may have some clinical relevance. This is due to im-
perfect sensitivity of BC [2], which was used as the reference
standard. Furthermore, PCR inhibition was never observed
during the analysis of a large number of clinical blood sam-
ples, demonstrating that the Polaris method is a robust proce-
dure for the preparation of human blood for multiplex PCR
not only in case of healthy human blood samples [28], but also
for critically ill patient samples.
The development of PCR assays for pathogen detection
directly in whole blood is technically challenging. This results
from low concentrations of circulating microbial DNA (relat-
ed to usual pathogen loads of 1 to 10 CFU/mL), as well as
high risk for inhibition of the PCR reaction due to an abun-
dance of human DNA and substances like hemoglobin [35,
36]. As a consequence, PCR sensitivity is highly influenced
by input sample volume and the method used for enrichment
of microbial DNA. In comparison to the 40 mL blood com-
monly drawn during routine BC, molecular assays have a
limited input volume (typically 1–10 mL), of which only a
Table 5 Specifies-specific PCR
detections in relation to blood
culture results
Species-specific PCR Congruent detection by BSI-PCR of 227 BC
isolates
Additional detected pathogens by BSI-
PCR
n Ct-value n Ct-value
E. faecalis 21 32.1 (29.6-36.1) 21 37.2 (36.6-38.8)
E. faecium 35 36.1 (33.9-37.2) 21 39.1 (36.6-40.0)
S. aureus 28 34.9 (32.9-37.0) 43 40.0 (39.2-40.0)
S. pneumonia 2 33.9 (27.7-40.0) 7 39.6 (36.8-40.0)
A. baumannii 0 4 33.6 (32.7-33.9)
E. coli 17 34.0 (30.4-34.6) 38 36.6 (35.9-37.4)
Klebsiella species 11 31.5 (27.7-33.8) 1 34.1
P. aeruginosa 27 34.6 (31.8-37.1) 34 40.0 (38.4-40.0)
C. albicans 0 - 0 -
C. glabrata 1 28.3 0 -
C. krusei 0 - 5 36.0 (34.5-40.0)
Total Positive 142 (63%) 34.4 (31.5-36.7) a 174 (4%) b 38.6 (36.3-40.0)
Results incorporate all detections of species-specific PCRS of BSI-PCR and blood culture (BC) in 218 BC-
positive (with 227 BC isolates) and 200 BC-negative samples, thus no selection criteria were applied for common
BC contaminants. Each sample was evaluated for 11 species-specific PCRs thus contributing 11 results. Data are
presented as frequencies, Ct-values as median (interquartile range)
a Ct-values were significantly lower in true positive than in discordant positive results (p<0.001)
b BSI-PCR identified 174 (4%) additional pathogens in 4371 PCRs evaluating pathogens not detected by BCs. Ct-
values of 84 detected pathogens by BSI-PCR were significantly higher in samples with complete negative BC
results than for detections in samples with positive BC (median 39.7 (IQR 37.0-40.0) versus Ct 37.4 (IQR 36.0-
40.0), p=0.01)
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fraction ends up in each individual PCR. The combined
Polaris and BSI-PCRmethod enables analysis of whole blood
samples of 5 mL, yielding an equivalent of 0.71 mL blood
input volume per PCR. This is considerably higher than most
other molecular BSI assays [36]. In our study, we could not
evaluate the effect of varying sample volume, but we did
assess the effect of bacterial load on sensitivity. Ct-values
were lower for true-positive than for false-positive PCR re-
sults, although we observed only a weak association between
BSI-PCR pathogen detection rates and viable bacterial load in
BC, deduced from TTP. This is most likely explained by the
fact that TTP varies intrinsically among pathogen.
Besides targeting high input volumes, we aimed to improve
PCR sensitivity by selecting multi-copy PCR targets on the
microbial genome whenever possible (Table 1). The benefit of
doing so is reflected by the observed difference between Ct-
values obtained for E. faecium detections using 1 PCR target
per genome (median Ct 36.1) and E. faecalis detections using
3–4 targets per genome (median Ct 32.1; Table 5). Of note,
CNS detection was not based on multi-copy targets for a sin-
gle PCR, but on positivity of either the MecA or the
Staphylococcus genus PCR (with negativity on the S. aureus
PCR). Simultaneous positivity on both PCRs was observed
only for samples with relatively higher CNS loads (i.e., low
MecA Ct-values; median 36.3 (IQR 35.6–38.1) versus 33.2
(IQR 32.1–34.3)). Apparently, the Staphylococcus genus PCR
is less sensitive than the MecA PCR for the detection of low
bacterial loads. This could be an advantage, since low CNS
loads may be of little clinical consequence and are frequently
caused by a contaminated blood draw.
Unfortunately, the detection of Candida species by BSI-
PCR in its initial multiplex set-up was poor. In fact, higher
sensitivities for fungal detection have been previously report-
ed for other molecular BSI assays, including the LSF and
T2Candida tests [8, 37]. This may be related to differences
in the methodology used to isolate DNA from Candida cells.
Both the LSF and T2Candida tests make use of a mechanical
lysis process, whereas BSI-PCR uses chemical methods.
Furthermore, in a trial evaluating the T2Candida assay, the
majority of samples tested were spiked with laboratory grown
Candida species rather than blood specimens obtained from
patients with true Candidemia [37]. This may have impacted
test performance as well. Indeed, during initial BSI-PCR de-
velopment, Candida detection was deemed satisfactory in
spiking experiments using laboratory-grown organisms. We
therefore hypothesize that Candida isolates derived from clin-
ical blood samples might be more difficult to process due to,
for example, changes in cell wall characteristics [38]. On a
Fig. 1 Time-to-positivity of blood culture in samples paired to true-
positive versus false-negative PCR results. Frequency distributions of
time-to-positivity are shown for 106 positive blood cultures associated
with correctly detected pathogens by BSI-PCR (true positive (TP), bars
with green border) and for 91 blood cultures with no congruent detection
by BSI-PCR (false negative (FN), bars with red border)
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similar note, we also observed inadequate detection by generic
PCRs targeting bacteria at their genus level as well as by the
molecular Gram stain. During early development of BSI-
PCR, specificity of the generic molecular Gram-stain PCRs
was increased by lowering cut-off Ct-values, even though this
inherently lowered their sensitivity.We opted for this trade off,
because of the increased risk of spuriously detecting blood
contamination (which typically involves low bacterial loads)
when using such broad generic PCR-targets. Since these
PCRs were primarily designed to broaden microbial coverage
of the test, their sensitivity will have only limited consequence
for its clinical utility overall. These generic PCRs are mainly
relevant for the minority of BSI cases where the causative
pathogen is not covered by species-specific PCRs [15, 16].
Evaluation of novel diagnostic methods may be hampered
by lack of a robust reference test [39]. This also applies to BSI-
PCR, as its comparator (BC) has imperfect sensitivity in a
setting of concurrent antimicrobial drug use [2]. Molecular
tests are in theory less affected by this, because they are
growth independent. Yet, we observed no effect of antimicro-
bial treatment on the rate of discordant positive BSI-PCR re-
sults. However, in fact, current knowledge about the kinetics
of microbial DNA clearance upon initiation of antimicrobial
treatment is very limited and in some cases this may be very
fast [40]. So the assumption of the sensitivity of PCRs being
robust during antimicrobial treatment may possibly be false.
Of note, the Polaris methodwas designed to isolate DNA from
intact pathogens only (dead or alive), but not cell-free DNA in
plasma. Another consequence of the high sensitivity of PCRs
also is an increased risk of discordant positive results due to
contamination from the environment. Future improvement in
producing DNA-free reagents may improve the utility of such
general bacterial PCRs as the molecular Gram stain.
As this was the first evaluation of BSI-PCR, we deliberate-
ly focused on test sensitivity rather than on a clinical interpre-
tation of discrepant positive results. For this purpose, we eval-
uated detection of a broad spectrum of microbes, while mak-
ing use of clinical blood samples. However, because we did
not enroll consecutive patients within a specific clinical do-
main, our study cannot provide estimations of positive and
negative predictive values of BSI-PCR. As a consequence,
test performance metrics (such as sensitivity and specificity)
of BSI-PCR cannot be directly compared with those published
for other molecular assays. In addition, we classified all path-
ogens detected by BSI-PCR but not by BC as Bdiscordant
positive^ spurious findings, whereas in a clinical setting these
might—in fact—be of relevance as illustrated by the concor-
dance with other culture results observed in our explorative
analysis. Thus, future studies will be necessary to further eval-
uate BSI-PCR performance and determine the clinical rele-
vance of BSI-PCR discordant positive results within their full
clinical context.In conclusion, sensitivity of BSI-PCR was
promising for the majority of bacterial species. However, a
better understanding of discordant positive results as well as
an improvement of detection rates for PCRs targeting yeasts
and bacterial groups are required before BSI-PCR can be com-
mercialized as a robust tool for pathogen identification in ICU
patients. Refinement of test sensitivity is currently focused on
the use of larger blood input volumes and implementation of
the BSI-PCR assay on a fully automated cartridge-base sam-
ple preparation and analysis platform. We thus expect BSI-
PCR to become available as a point-of-care test, requiring
only very little hands-on manipulation and yielding overall
turnaround times of approximately 3 h.
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